How many investments has Oxford Science Enterprises made?

Oxford Science Enterprises has 104 tracked investments, 3 of which have exited, including 9 dated in the last 24 months.

What stage does Oxford Science Enterprises invest at?

Oxford Science Enterprises invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth stages.

What is Oxford Science Enterprises's typical check size?

Oxford Science Enterprises typically writes checks of $63.5K – $31.8M.

Where is Oxford Science Enterprises located?

Oxford Science Enterprises is headquartered in Oxford, GB.

Does Oxford Science Enterprises lead rounds?

Yes, Oxford Science Enterprises leads investment rounds.

Who does Oxford Science Enterprises co-invest with?

Oxford Science Enterprises most often shares deals with Future Planet Capital, Perivoli Innovations, GV (Google Ventures), among 91 tracked co-investors.

Oxford Science Enterprises

Venture studiooperating company · company profile

Oxford · Pre-Seed–Growth · 71 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Oxford Science Enterprises

Paths you didn't know you had: your email and LinkedIn already hold routes to the Oxford Science Enterprises team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

Oxford Science Enterprises operates as a venture builder in partnership with the University of Oxford, transforming academic breakthroughs into commercial companies. Working with researchers across Oxford, Harwell and Culham, it identifies bold scientific ideas, funds them with patient capital from pre-seed to growth stages, and builds transformational ventures. The firm focuses on deep tech, life sciences and healthtech, aiming to create world-changing, billion-pound companies while delivering strong returns for investors. It has raised over £850m from global investors and, together with co-investors, has deployed more than £3bn across its portfolio of flagship companies.

Invests inAgTech AI & Machine Learning Biotech Cleantech Climate Tech Deep Tech Energy Healthtech Medical Devices Quantum Computing RoboticsSector AgnosticEurope North America Oxford United Kingdom

Source: firm website, verified Sep 27, 2026.

Leave your own feedback

Stage

Pre-Seed–Growth

Check

$63.5K – $31.8M

Oxford, GB

Leads rounds

Leads

Instruments

Equity

Founded

2015

Last 12 months

7 investments

AUM

$1.1B

Tracked investments

104

IPOs

Acquisitions

Team · 71 people

from the firm's website & curated & public directories

Craig Fox· Operating Partner, Life Sciences· United Kingdomin

Katherine Ward· Operating Partner, HealthTech· Greater Bristol Area, United Kingdomin

Katherine Ward is an Operating Partner at Oxford Science Enterprises, where she focuses on venture building in health technology. She has more than 30 years of global healthcare experience spanning the government and private sectors, with expertise in general management, business development, strategy, and team building.

Lilly Bussmann· Partner· Oxford, United Kingdomin 𝕏

Nicholas Dixon-Clegg· Partner, Head of Independent Investments· Londonin

Oliver Mahony· Partner, Independent Investments

Polly Elvin· Partner, Capital Formation & Investor Relations

Claire Brown· Partner· Oxford, United Kingdomin

Claire Brown has over 20 years of biopharmaceutical experience across the UK and US, spanning R&D strategy, licensing, business development and corporate investment. At OSE she leads company creation and portfolio strategy in Life Sciences, having joined in 2020 after roles at UCB, Sanofi-Genzyme, AstraZeneca and as Head of Investment at Pioneer Group.

cbrown@oxfordsciences.com

Heather Roxborough· Senior Partner, Head of HealthTech· Oxford

Heather leads OSE's HealthTech investment team across digital health, diagnostics, medical devices and life science tools, with over 20 years in healthcare innovation and venture investing. Before joining OSE in 2022 she was a Partner at Optum Ventures leading its Global HealthTech fund, and previously held roles at Unilever and Johnson & Johnson; she holds a PhD in Clinical Biochemistry from Queen's University Belfast.

hroxborough@oxfordsciences.com

Jack Edmondson· Chief Investment Officer· Oxford

Jack Edmondson leads OSE's investment strategy and oversees all investment activity across Life Sciences, Deep Tech and HealthTech. He joined in 2023 after 14 years as Deputy CIO at Oxford University Endowment Management, and previously worked at Exponent Private Equity, McKinsey and Merrill Lynch. He holds an Oxford MBA, a Durham BA, and is a CFA Charterholder who also teaches finance at Oxford's business and government schools.

jedmondson@oxfordsciences.com

Joel Schoppig· Partner, HealthTech· Oxfordin 𝕏

A HealthTech operator turned investor who joined OSE from Pitango, where he was an investment principal on early-stage HealthTech deals. Earlier he was a founding team member and VP of Strategy and BD at Healthy.io, and previously advised Nigeria's Ministry of Health on healthcare financing.

jschoppig@oxfordsciences.com

Sam Harman· Partner, Head of Deep Tech· Oxfordin

Sam Harman leads OSE's Deep Tech investment team, overseeing the pipeline, supporting new company creation and guiding portfolio growth, with experience across AI, semiconductors, compute and space. He joined OSE in 2019 after working in management consulting on AI solutions, and holds a first-class master's in PPE from the University of Oxford.

sharman@oxfordsciences.com

Sanne de Jongh· Partner, Life Sciences· Oxfordin

Sanne De Jongh invests across therapeutic areas and development stages with over a decade of biotech VC experience. She joined OSE in February 2023 after roles at Gilde Healthcare, Anterra Capital and M Ventures, and holds degrees from Leiden University and Delft University of Technology.

sdejongh@oxfordsciences.com

George Todd· Principal, Deep Tech· London, England, United Kingdomin

George Todd is a Principal at Oxford Science Enterprises. He invests in deep tech companies from pre-seed to Series B stages and serves as a non-executive director and venture builder.

Lauren Laing· Principal, HealthTech

Liliane Chamas· Principal, HealthTech

Richard Oakley· Principal, Deep Tech· Oxford, England, United Kingdom

Tony Besse· Principal, HealthTech· London, England, United Kingdomin

Sally Dewhurst· Principal, Life Sciences· Oxford

Sally Dewhurst focuses on creating new biotech businesses, drawing on deep oncology research expertise to translate cutting-edge science into company formation. She joined OSE in February 2021, following a post-doctoral fellowship at Rockefeller University and a PhD at the Francis Crick Institute, and has also studied corporate finance at NYU.

sdewhurst@oxfordsciences.com

Jeff Moore· Senior Partner, Head of Life Sciences

Paul Galluzzo· Entrepreneur-in-Residence, HealthTech

Alex Hammacher· Head of Strategic Operations & Corporate Finance· London, England, United Kingdomin

Alicia Mederick· Team Co-ordinator

Andre Crawford-Brunt· Non-Executive Director

email@email.com

Andrew Straiton· Senior Associate, Deep Tech· London, England, United Kingdomin

Andrew Straiton is a Senior Associate in Deep Tech at Oxford Science Enterprises, where he invests across the physical sciences and engineering, with a focus on energy and industrials. He holds a PhD in applied inorganic materials chemistry from the University of Bath and previously worked as a management consultant at Bain and Company.

Andy Penfold· Content Lead

Antonia Jenkinson· Chief Financial Officer· United Kingdomin

Antonia Jenkinson is Chief Financial Officer at Oxford Science Enterprises, working in the science and technology sector across areas including frontier science, fusion energy, and space. Her background spans corporate finance and leveraged private equity-backed companies, with five exit transactions completed in CFO and Non-Executive Director capacities. She holds four Non-Executive Director and Chair of Audit positions and has received the Sunday Times NED award.

Athene Blakeman· General Counsel· London, England, United Kingdomin

Athene Blakeman is General Counsel at Oxford Science Enterprises, with in-house and corporate finance experience spanning 16 years, including roles at top private practice firms. From 2014 to 2019, she served as General Counsel, Company Secretary and Executive Team member of Benchmark Holdings plc, an AIM-listed international aquaculture and biotechnology group, before becoming Managing Director of Benchmark Advanced Nutrition and CEO of INVE Aquaculture, a $100m turnover aquaculture nutrition business, from 2019 to 2021. Her work covers corporate governance, listed company obligations, share schemes, commercial contracts, risk management, compliance, intellectual property, litigation, and M&A and fundraising transactions.

Benny Axt· Entrepreneur-in-Residence, HealthTech· Oxford, England, United Kingdom

Bernard Taylor· Non-Executive Director· Greater London, England, United Kingdom

Céline Leclere· Executive Assistant, HealthTech

Charo Bajo· Data & Projects Manager· Greater Oxford Areain

Charo Bajo is Data & Projects Manager at Oxford Science Enterprises. Her background includes programme leadership at operational and strategic levels, along with external and internal engagement within networked organisations, and she has developed capability programmes in Tanzania, India, China, and the Philippines. She holds a Lean Six Sigma Green Belt Practitioner certification.

Chris Chambers· Non-Executive Chairman

Christopher Ashton· Advisor, Life Sciences

Clare Gumbley· Portfolio Talent Lead, Life Sciences

Daoud Khan· Finance Manager· London, England, United Kingdomin

Daoud Khan is a CIMA-qualified finance professional with over five years of experience across multi-entity, start-up, and investment fund settings. As Finance Manager at Oxford Science Enterprises, a £1 billion venture capital firm, he oversees fund-level reporting, valuations, and audits, and works with senior leadership on budgeting, forecasting, and performance management. His secondment work has included developing revenue-recognition playbooks, 13-week cashflow models, and board reporting materials.

Emily Matthews· Responsible Investment & ESG Manager

Fiona Murray· Non-Executive Director

Gaëlle Newton· Events Manager

Harry Clifford· Entrepreneur-in-Residence, HealthTech· Cambridge, England, United Kingdomin

Harry Clifford is a biotech entrepreneur focused on digital biology and AI, currently serving as an Entrepreneur in Residence at Oxford Science Enterprises. His prior experience includes developing healthcare products at NVIDIA and co-founding a Y Combinator-backed precision oncology startup. He completed a PhD at the University of Oxford and a postdoctoral position at the University of Cambridge.

Iwona Dombek-Wieczorek· Finance Officer· Greater Oxford Areain

Jack Strudley· Head of Finance· Oxford, England, United Kingdomin

James Finlayson· Entrepreneur-in-Residence, Deep Tech· Greater London, England, United Kingdom

Jeanette Lovis· Executive Assistant

John Roberts· Senior Compliance Manager

Jon Wall· Portfolio Talent Lead, Deep Tech· Greater London, England, United Kingdomin

Jon Wall is Portfolio Talent Lead at Oxford Science Enterprises, an independent investment company and venture builder that develops companies based on scientific research. In his role, he works with investors and portfolio companies to build leadership teams for deep tech enterprises across sectors including energy transition and decarbonisation, quantum computing, AI, space tech, and health tech.

Lisa Bedwell· Head of Marketing· Oxford, England, United Kingdomin

Lisa Bedwell is Head of Marketing at Oxford Science Enterprises, which she joined as Senior Communications Manager in September 2020. She previously served as Communications Manager at Medicines Discovery Catapult and has over ten years of experience in the pharmaceutical and biotechnology industries, including work with US-based biotech start-ups. She holds a BSc in Psychology and an MSc in Developmental Cognitive Neuroscience from Durham University.

Mark Chadwick· Scientist-in-Residence, Deep Tech· London Area, United Kingdomin

Mark Chadwick is a Scientist in Residence at Oxford Science Enterprises, where he works with academics and founders to commercialize research from Oxford University. He previously spent 15 years as a research scientist in academia at universities in the UK and mainland Europe, running his own research programme, publishing peer-reviewed articles, and securing research grants and fellowships.

Marlou Hanselmann· Communications & Digital Marketing Executive

Martin Fiennes· Advisor, Deep Tech· Oxford, United Kingdomin 𝕏

Martin Fiennes is a Deep Tech Advisor at Oxford Science Enterprises, a £850 million investment company that develops and scales spinouts from research across the Mathematical, Physical, Life Sciences, and Medical Sciences divisions at the University of Oxford. He serves as a Non-Executive Director.

Matt Myers· Senior Associate, Independent Investments· Cambridge, England, United Kingdomin

Matt Myers is a Senior Associate at Oxford Science Enterprises and a Chartered Engineer. He has experience in venture capital and engineering, along with project and people management.

Matt Nicholls· Advisor· Greater Reading Areain

Matthew Nicholls is Senior Tutor at St John's College, Oxford, and a Visiting Professor of Classics at the University of Reading, where he worked from 2007 before taking up his Oxford role in 2019. He holds MA, MPhil, and DPhil degrees from the University of Oxford, received a National Teaching Fellowship in 2017 and a Guardian/Higher Education Academy teaching award in 2014, and was elected a Fellow of the Society of Antiquaries in 2023. His research focuses on the city of Rome, including a digital 3D reconstruction of the ancient city, and on ancient books and libraries in the Roman world, and he has authored 30-Second guides to Ancient Rome and Ancient Greece.

Matthew Hunt· Legal Counsel· United Kingdomin

Molly Stevens· Non-Executive Director

Nico Babaian· Entrepreneur-in-Residence, HealthTech

Pete Wilder· Head of Property & Operations

Peter Donnelly· Non-Executive Director

Peter Weston-Smith· Senior Associate, HealthTech

Rachel McKee· Senior People Advisor· High Wycombe, England, United Kingdomin

Rachel McKee is a Senior People Advisor at Oxford Science Enterprises, where she provides advisory, strategic, and administrative support across the employee life cycle. Her responsibilities include recruitment, onboarding, benefits, payroll, and wellbeing.

Richard Hobbs· Non-Executive Director

Sam Harris· Senior Associate, Capital Formation & Investor Relations

Sami Walter· Senior Associate, Deep Tech· London, England, United Kingdomin

Sami Walter is a Senior Investment Associate at Oxford Science Enterprises. Walter's work focuses on venture building and investing in early-stage deep tech companies.

Satoko Robertson· Executive Assistant & Legal Secretary

Sive Ozer· Head of Legal, Investing· Greater London, England, United Kingdomin

Snigdha Lal· Associate, Deep Tech

Suzanne Algie· Team Co-Ordinator, Life Sciences· Ambrosden, England, United Kingdom

Tatiana Lobanov-Rostovsky· Associate, HealthTech· United Kingdomin

Wallace Wallace· Senior Associate, Independent Investments

William Goodlad· Advisor, Deep Tech· London

Ed Bussey· CEO· Oxfordin

Ed Bussey is CEO of Oxford Science Enterprises, joining in September 2023 with over 20 years of business leadership and venture-building experience. A serial entrepreneur, he founded and exited three technology businesses (figleaves.com, ZYB, and Quill) and sits on the Oxford-Cambridge SuperCluster Board. He studied finance at INSEAD and holds a BA in Natural Sciences from Cambridge.

ebussey@oxfordsciences.com

Katharina Ramshorn· Senior Associate, Life Sciences· Oxford

Katharina supports the creation and growth of biotech ventures, drawing on her background in biochemistry and immunology. She holds a PhD in Immunometabolism and an MRes from the University of Cambridge and a BSc from the University of Leeds, joined OSE in May 2023, and previously interned in life science investment at Cambridge Innovation Capital.

kramshorn@oxfordsciences.com

Katya Smirnyagina· Advisor, Life Sciences· Oxford

A venture capitalist with over 20 years in biotechnology, Katya joined Oxford Science Enterprises in September 2021 and leads the Life Sciences team, supporting academic founders from early development to go-to-market. She previously worked at Alta Partners and Capricorn Partners and is a former Vice-Chair of InvestEurope. She holds a PhD in Cellular & Molecular Biology from the University of Wisconsin-Madison and completed a post-doc at Stanford University School of Medicine.

ksmirnyagina@oxfordsciences.com

Founder mafia

3 people who came through Oxford Science Enterprises went on to found or lead other companies.

Damian CrowtherConsultantFounded TRIMTech Therapeutics Walter GoodwinAssociateFounded Fractile Daniel McMahonVenture BuilderFounded Snowfox Discovery

What they invest in

from 63 of 104 portfolio companies

Deep Tech ×34AI & Machine Learning ×29Biotech ×24Hardware ×18Healthtech ×18Medical Devices ×16Cleantech ×10Digital Health ×9

HQs:United Kingdom×35United States×4Luxembourg×1

Who they back

founder profiles across 26 portfolio companies

38%

solo founders

10 of 26 mapped founding teams

12%

repeat founders

of 26 founders with career history

~5.5 yrs

old at investment

median across 8 dated deals

Founding team size:solo founder×102 founders×83 founders×14+ founders×7

Where their founders studiedfrom 19 founders with education data

University of Oxford ×7Imperial College London ×2

What their founders studiedfrom 25 founders with field-of-study data

Engineering ×8Physics ×7Chemistry ×4Computer Science ×3Life Sciences ×3Medicine ×3Mathematics & Statistics ×2

Where their founders worked beforefrom 26 founders with career history

University of Oxford ×16IBM ×2

21 founders hold a PhD (of 25 with degree data)

Investments · 104 tracked

founders shown can be your intro path

By year:2026 · 5 2025 · 4 2024 · 2 2023 · 6 2022 · 4 2021 · 3 2019 · 125 dated

Barinthusbiobarinthusbio.com in 𝕏NASDAQ: BRNS

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies designed to guide T cells to treat autoimmune and inflammatory diseases.

BiotechHealthtechMedical Devices

Geoffrey Lynn(Chief Scientific Officer)William Enright(Chief Executive Officer & Board Director)Leon Hooftman(Chief Medical Officer)

Co-investorsFuture Planet Capital GV (Google Ventures)Milltrust International Group Xfund

PepGenpepgen.com in 𝕏NASDAQ: PEPG

PepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.

AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US

James McArthur(Executive Officer, Director)inNoel P. Donnelly(Chief Financial Officer)in Joseph D. Vittiglio(Chief Business & Legal Officer and Secretary)inKasra Kasraian(Chief Technical Officer)in

Board Ramin Farzaneh-Far(Director)inJoshua Resnick(Director)

Co-investorsRA Capital Viking Global

Beacontxbeacontx.com in 𝕏✓ verified

Beacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.

BiotechDigital HealthMedical Devices

Daniel Chung(Chief Medical Officer)in Lance Baldo(Chief Executive Officer)in Abraham Scaria(Chief Scientific Officer)in

Co-investorsAdvent Life Sciences Forbion TCG Crossover

Bullhound Capitalbullhoundcapital.com in✓ verified

Sereact builds AI foundation models that enable industrial robots to perform complex manipulation tasks like warehouse picking and returns handling without retraining.

Advanced ManufacturingAI & Machine LearningDeep TechEnterprise SoftwareQuantum ComputingRoboticsOxford, GB

Ralf Gulde(CEO and co-founder)Marc Tuscher(CTO and co-founder)Gerald Mullally(CEO)

Co-investorsAlpha Edison British Business Bank Chevron Technology Ventures Invus Backstage AB

Dark Blue Therapeuticsdarkbluetx.com in✓ verified

Dark Blue Therapeutics develops novel medicines for cancer through integrated drug discovery combining internal expertise with academic partnerships.

BiotechDeep TechHealthtechLondon, GB

Alastair MacKinnon(Chief Executive Officer)in

Mode Labsmodelabs.tech inMay 2025✓ verified

ModelLabs develops open microcavity sensing technologies for remote environmental monitoring.

AI & Machine LearningCleantechClimate TechDeep TechHardwareQuantum ComputingOxford, GB

Daniel Miles-Barrett(CTO)Prof. Jason Smith(Academic Founder)Dean James(CEO)in

Omassomass.com in 𝕏✓ verified

OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs.

BiotechDeep TechDigital HealthHealthtechMedical DevicesOxford, GB

Professor Dame Carol Robinson(Founder and Chair of Scientific Advisory Board)Idlir Liko(Founder)inJonathan Hopper(Vice President, Platforms and Founder)inHsin Yung (Jason) Yen(Founder)in Ros Deegan in

Co-investorsGV (Google Ventures)Sanofi Ventures Northpond Ventures

Opsydiaopsydia.com in✓ verified

Opsydia develops optical and photonic technologies for precision manufacturing, emerging from research in adaptive optics and laser processing at the University of Oxford.

Advanced ManufacturingAI & Machine LearningDeep TechHardwareNew MaterialsSemiconductorsOxford, GB

Martin Booth(Founder and Director)inPatrick Salter(Founder and Director)inDr. Noel Moore(Chief Technology Officer)

BoardNigel Vaughan(Chairman)

Co-investorsForesight Group Oxford University Innovation Parkwalk Advisors

Oxford Quantum Circuitsoxfordquantumcircuits.com in 𝕏✓ verified

Oxford Quantum Circuits (OQC) develops and operates superconducting quantum computers for commercial and strategic applications, offering Quantum-Compute-as-a-Service and integrating quantum systems directly into commercial data centres.

Deep TechEnterprise SoftwareHardwareQuantum ComputingOxford, GB

Peter Leek(Founder & CSO)inGerald Mullally(CEO)in Simon Phillips(CTO)inNikki Cooper(CLO)in Robert Coutts(CFO)in

BoardJack Boyer(Chairman of the Board)

Co-investorsBritish Business Bank Oxford Oxford Investment Consultants LLP UTEC

Refeynrefeyn.com in✓ verified

Refeyn develops mass photometry instruments that measure the mass of individual biomolecules in solution without labels, enabling analysis of protein purity, interactions, and viral vector characterization for research and manufacturing applications.

BiotechDeep TechHardwareMedical DevicesOxford, GB

Philipp Kukura(Founder)Dan Cole(Chief Scientist and co-founder)inJustin Benesch(Co-founder)in

Co-investorsForesight Group Horizons Ventures Oxford Technology Management

Seloxiumseloxium.com in✓ verified

Seloxium develops a metal recovery and refining technology (branded "Selectal") used for tailings reprocessing, wastewater treatment, bulk metal recovery, and high-purity refining.

Circular EconomyCleantechDeep TechNew MaterialsTeesside, GB

Christian Peters(CEO & Co-founder)inSteve Colley(Co-founder, Technical Advisor & Director)Nick Hankins(Co-founder, Scientific Advisor & Director)Steve van Zutphen(Co-founder, CEO Advisor)Dr Richard Dixon(CCO)Roberto Ricci(CFO)in

Co-investorsOxford Investment Opportunity Network (OION)Empirical Ventures

Singular Machinessingularmachines.co.uk✓ verified

Singular Machines develops AI-native engineering tools for designing complex machines, facilities, and infrastructure in the advanced manufacturing sector.

Advanced ManufacturingAI & Machine LearningDeep Tech

Co-investorsUK Innovation & Science Seed Fund

Sitryxsitryx.com in 𝕏✓ verified

Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism.

BiotechDeep TechHealthtech

Co-investorsLongwood Fund Sofinnova Partners SV Health Investors Dementia Discovery Fund

Snowfox Discoverysnowfoxdiscovery.com inJan 2025✓ verified

Snow Fox Discovery explores for and develops natural (geologic) hydrogen resources, aiming to supply low-carbon hydrogen for a net-zero energy transition.

CleantechClimate TechEnergy

Daniel McMahon in

Co-investorsAP Ventures Oxford bp ventures

Theolyticstheolytics.com✓ verified

Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.

BiotechHealthtech

Co-investorsEpidarex Capital Sound Bioventures Taiho Ventures, LLC M Ventures

Ultromicsultromics.com in 𝕏✓ verified

Ultromics develops AI models that analyze routine echocardiography studies to help clinicians detect HFpEF and screen for cardiac amyloidosis, delivered through a single workflow platform.

AI & Machine LearningDigital HealthMedical Devices

Ross Upton(Founder & CEO)in

Co-investorsGV (Google Ventures)Legal & General Future Planet Capital Nina Capital NovaCapital Optum Ventures +2 more

Aisteticaistetic.com in

AI-powered platform for online fashion designed to simplify the shopping experience.

AI & Machine LearningE-commerceMarketing TechRetail TechSaaSAbingdon, GB

Duncan McKay(Founder & CEO)inPhil Torr(Founder & Chief Technologist)in

Co-investorsTechstars Loyal VC

Allosallos.ai

Allos offers an AI platform that simulates how process interventions affect outcomes to define robust operating windows before physical experiments are run, supporting pharmaceutical development from formulation through scale-up, tech transfer, QA, and clinical trials.

AI & Machine LearningBiotechHealthtech

Co-investorsOxford University Innovation

Alveogenealveogene.com inSeed · Sep 2023

AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.

BiotechDeep TechDigital HealthHealthtechMedical Devices

David Hipkiss(Executive Chair)in

Amber Therapeuticsamber-tx.com in

Amber Therapeutics develops medical technology focused on treating mixed urinary incontinence, advancing toward pivotal clinical trials in the US with expanded feasibility studies in Europe.

Medical Devices

Co-investorsF-Prime Capital Intuitive Ventures Lightstone Ventures New Enterprise Associates (NEA)

Archangelarchangel.works inApr 2026 · $13.5M

Archangel builds laser (optical) communication systems that connect satellite networks in space with terrestrial networks, offering an alternative to radio frequency and subsea cable infrastructure.

Deep TechHardwareSpace Tech

Co-investorsBlackfinch Ventures Oxford

BehaVRbehavr.com in 𝕏Jan 2023

BehaVR develops VR-based (XR) therapeutics for mental and behavioral health, translating clinical science into immersive programs that address stress, anxiety, fear, pain management, addiction recovery, and maternal health.

Digital HealthHealthtechMental HealthElizabethtown, US

Aaron Gani(Executive Officer, Director)

Co-investorsChrysalis Ventures Keyhorse Capital Poplar Ventures Accenture Ventures Frist Cressey Ventures Future Labs Capital +1 more

Bibli Ubibliu.com in 𝕏Series B · Jun 2022 · $15M

BibliU is a digital learning platform that partners with publishers to provide students affordable, instant access to course content, and offers institutions workflow automation to reduce administrative burden.

EdTechSaaS

Dave Sherwood(CEO & Co-Founder)in

Co-investorsBrick Capital Ventures Green Shores Capital Guinness Ventures Kreos Capital Parkwalk Advisors Beyond Ventures +4 more

Caristo Diagnosticscaristo.com in 𝕏Apr 2023

University of Oxford spinout whose imaging technology aids diagnosis and treatment of cardiovascular disease.

Co-investorsBusiness Growth Fund Creative Destruction Lab (CDL)Longwall Venture Partners LLP Oxford Investment Consultants LLP

Covaticcovatic.com in 𝕏

Covatic develops an on-device advertising platform powered by AI and machine learning that identifies user cohorts and delivers targeted ads while preserving consumer privacy.

AdTechAI & Machine LearningIoTLondon, GB

Nick Pinks(Founder)in

Co-investorsCreative UK Oxford Technology Management Techstars Techstars Ventures 2022

Densixdensix.com

Densix develops high power-density power converters aimed at applications including data centres, power grids, EV charging, and renewable energy.

CleantechEnergyHardware

Co-investorsOxford University Innovation

DiffBluediffblue.com in 𝕏

Diffblue offers an AI-powered solution that automatically generates Java unit tests, freeing developers from manual test writing.

AI & Machine LearningDeveloper ToolsEnterprise Software

Co-investorsAlbionVC Perivoli Innovations IP Group

EndLyz Therapeuticsendlyz.com in

Endlyz develops small-molecule disease-modifying therapeutics targeting the ATP13A2 and ATP10B lysosomal transporters to restore endo-lysosomal function and counter neurodegeneration.

BiotechDeep TechBoston, US

Joanna Wolak(Executive Officer, Director)inJonathan Behr(Director)John Gustofson(Director)Damian Crowther(Director)Zaven Kaprielian(Executive Officer, Director)

Board Laurence Barker(Director)

Co-investorsDementia Discovery Fund

Evolitoevolito.aero

Evolito develops and manufactures electric propulsion and power generation systems for aerospace, including electric engines, motors, and motor control systems for type-certifiable and volume-manufactured applications.

CleantechHardwareMobility & Transportation

Co-investorsPerivoli Innovations

Evox Therapeuticsevoxtherapeutics.com in 𝕏

Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.

BiotechDeep Tech

Co-investorsGV (Google Ventures)OrbiMed Panacea Venture Cowen Healthcare Investments REDMILE

First Light Fusionfirstlightfusion.com in 𝕏

First Light Fusion develops fusion energy technology through experimental validation of projectile-based fusion concepts and computational modeling for inertial confinement fusion applications.

CleantechDeep TechEnergyOxfordshire, GB

Yiannis Ventikos(Founder)Nicholas Hawker(Founder)

Co-investorsSalica Investments IP Group

Fluorokfluorok.com in 𝕏

FluoRok, a spin-out of the University of Oxford, develops patented fluorinating technologies to produce fluorochemicals such as Li-ion battery electrolytes, agrochemicals, and pharmaceutical ingredients without generating toxic hydrofluoric acid.

CleantechDeep TechNew Materials

Gabriele Pupo(CEO & Founder)inVéronique Gouverneur(Founder)in

Co-investorsExcellis Holding GGF Green Generation Fund Business Growth Fund Club degli Investitori ePlanet Capital

Fractilefractile.ai inJul 2024

Fractile designs processors for AI acceleration, offering the next generation of computing hardware.

AI & Machine LearningDeep TechHardwareSemiconductorsBristol, GB

Walter Goodwin(Founder)in

Co-investors01 Advisors Accel Factorial Funds Felicis Ventures Gigascale Capital Inovia Capital +9 more

Genomics Plcgenomics.com in 𝕏

Genomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers.

AI & Machine LearningBiotechDigital HealthHealthtechOxford, GB

Peter Donnelly(Founder)inDr Chris Spencer(Founder)Dr Gerton Lunter(Founder)Gilean McVean(Founder)Professor Gil McVean(Founder)Professor Sir Peter Donnelly(Founder)

Co-investorsF-Prime Capital Foresite Capital Salica Investments IP Group

Grey Wolf Therapeuticsgreywolftherapeutics.com inMay 2024 · $50M

Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.

BiotechDigital HealthHealthtechMedical DevicesOxford, GB

Peter Joyce(Co-founder)inTom McCarthy(Co-founder)in

Co-investorsAndera Partners Canaan Partners Pfizer Venture Investments British Patient Capital Earlybird Venture Capital Pfizer Ventures

Iota Sciencesiotasciences.com

Delivering single cells to advance research and medicine

Co-investorsFuture Planet Capital Oxford Investment Opportunity Network (OION)

Living Opticslivingoptics.com in 𝕏

Living Optics develops hyperspectral imaging cameras and software that enable users to capture and analyze hidden details in images across applications in food, healthcare, security, and industrial markets.

AI & Machine LearningDeep TechHardwareMedical DevicesOxford, GB

Co-investorsOctopus Ventures

Marley Healthmarleyhealth.com

Marley Health combines veterinary and human healthcare expertise with machine learning and technology to develop healthcare solutions.

AI & Machine LearningConsumerHealthtechMedical Devices

Nate Notwell(Co-founder & CEO)Dr Amanda Boag(Co-founder & CMO)Dr Jenny Wilshaw(Co-founder & Head of Data)Prof David Clifton(Co-founder & Technology Advisor)

Mind Foundrymindfoundry.ai in

Mind Foundry develops deployed AI and machine learning systems for high-risk, high-complexity operational domains, including defense applications such as multi-sensor data fusion for battlespace situational awareness and threat-signature analysis.

AI & Machine LearningDeep TechDefense Tech

Stephen Roberts(Co-founder)inMichael Osborne(Co-founder)

Co-investorsParkwalk Advisors

Mixergymixergy.co.uk in 𝕏

Mixergy manufactures smart hot water cylinders with patented heating technology and machine learning controls that reduce energy consumption by up to 40%.

CleantechClimate TechEnergyHardwareIoTUK, GB

Pete Armstrong(Founder)Ren Kang(Founder)

Co-investorsIP Group Kiko Ventures

NavLivenavlive.ai in 𝕏

NavLive provides a handheld scanning device and cloud platform that captures point clouds and generates 2D floor plans, elevations, and sections in real time using multi-sensor SLAM tracking and AI feature detection.

AI & Machine LearningConstruction TechHardwarePropTech

David Wisth(Founder)in

Co-investorsClearance Venture Partners Oxford Trimble Ventures

Nucleomenucleome.comOct 2022

Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.

AI & Machine LearningBiotechDeep Tech

Co-investorsM Ventures Pfizer Venture Investments British Patient Capital JJDC Pfizer Ventures

NVISIQnvisiq.com

nVisiq develops passive 3D perception systems designed for long-range, high-resolution sensing that operates across varied and difficult environments.

AI & Machine LearningDeep TechHardware

Co-investorsCelero Ventures Ltd.

ONIoni.bio in 𝕏Jan 2022 · $75M

ONI develops the Nanoimager, an automated super-resolution imaging system.

BiotechDeep TechHardwareMedical DevicesOxford, GB

Co-investorsAnjost ARCH Venture Partners Artis Ventures Future Planet Capital Oxford Technology Management Vertical Venture Partners +6 more

Orbit Discoveryorbitdiscovery.com in 𝕏Seed · Jul 2021 · $8M

Orbit Discovery provides peptide discovery solutions for pharmaceutical and biotechnology companies, serving both large pharmaceutical firms and smaller biotech enterprises.

AI & Machine LearningBiotechDeep TechHealthtechOxford, GB

Neil Butt(CEO)in

Co-investorsFuture Planet Capital Oxford Technology Management Perivoli Innovations Borealis Ventures

ORCA Computingorcacomputing.com in 𝕏

ORCA Computing develops full-stack photonic quantum computing systems, including on-premises hardware and software tools, for research institutions, government bodies, and industry applications such as generative AI, machine learning, and optimisation.

AI & Machine LearningDeep TechHardwareQuantum ComputingLondon, GB

Ian Walmsley(Founder)in Richard Murray(Founder)inJosh Nunn(Founder)in Per Nyberg(Chief Commercial Officer)inMike Piraino(Chief Operating Officer)Thien-An Nguyen(Chief Technology Officer)in

Co-investorsInnovating Capital Octopus Ventures Perscitus LLP Quantonation Verve Ventures Atmos capital

Oxford Flowoxford-flow.com in

Oxford Flow manufactures precision valves and regulators using a single-piston design for oil & gas, hydrogen, and water infrastructure.

Advanced ManufacturingCleantechEnergyHardwareOxford, GB

Co-investorsEnergy Impact Partners Future Planet Capital bp ventures

Oxford Ionicsoxionics.com in 𝕏Jan 2023

Oxford Ionics develops trapped-ion quantum computers using proprietary Electronic Qubit Control technology, designed for businesses to deploy quantum computing applications.

Deep TechHardwareQuantum Computing

Co-investorsOxford University Innovation 2xN Lansdowne Partners Prosus Ventures

Oxford Semantic Technologiesoxfordsemantic.tech in 𝕏

Oxford Semantic Technologies develops RDFox, an in-memory knowledge graph and semantic reasoning engine that uses logic-based inference to deduce new facts and deliver explainable, auditable results for AI applications.

AI & Machine LearningData & InfrastructureDeep TechOxford, GB

Ian Horrocks(Co-founder)in Peter Crocker(Founder)in

Perspectumperspectum.com in 𝕏

Perspectum develops digital medical technology and diagnostics using multiparametric MRI to assess and diagnose chronic systemic diseases including liver disease, long COVID, diabetes, and cancer for clinicians and patients.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesOxford, GB

Rajarshi Banerjee(CEO)in

Co-investorsBlue Venture Funds British Patient Capital HealthQuest Capital Sandbox Industries

PQShieldpqshield.com in 𝕏Jan 2022 · $20M

PQShield develops post-quantum cryptography (PQC) products, including optimized software libraries, SDKs, OpenSSL integration layers, and lattice-based hardware IP cores, to help organizations migrate systems to quantum-resistant cryptography.

CybersecurityDeep TechQuantum ComputingSemiconductors

Co-investorsBY Venture Partners Crane Venture Partners Kindred Capital Addition Chevron Technology Ventures

Prolificprolific.com in 𝕏Series A · Jul 2023

Prolific connects researchers, AI developers, and product teams with vetted participants for collecting high-quality human data for AI training, surveys, and behavioral research.

AI & Machine LearningData & InfrastructureEnterprise SoftwareMarketplacesSaaSLondon, GB

Phelim Bradley(CTO)inSam Harman(Director)Enrico D'Angelo(Director)Meenakshi Parameshwaran(Data Scientist)Matt Tuplin(Vice President of Engineering)Chloe Sheppard(Talent Manager)

Co-investors10xvaluepartners Y Combinator Altaclub VC AltaIR Capital Partech Ventures Pioneer

Prolificprolific.coJul 2023 · $32M

Prolific operates an online platform connecting researchers and AI/ML developers with verified human participants who complete paid studies, providing human data and feedback for research and for AI tasks like preference tuning, safety evaluations, and benchmarks.

AI & Machine LearningData & InfrastructureMarketplaces

Co-investorsPartech Ventures Pioneer

Proxisenseproxisense.com

Proxisense develops high-performance sensors for monitoring manufacturing processes and diagnostics, with origins in aerospace and defence applications.

Advanced ManufacturingDeep TechHardwareIoTMedical DevicesOxford, GB

Paul Vickery(Founder and Chairman)Kam Chana(Founder and NED)

Co-investorsFuture Planet Capital Parkwalk Advisors

Quantum Motionquantummotion.tech

Quantum Motion develops utility-scale quantum computers using silicon spin-qubit architecture compatible with standard semiconductor manufacturing processes and existing foundry supply chains.

Deep TechQuantum ComputingSemiconductors

Co-investorsBosch Ventures DCVC (Data Collective)Inkef Octopus Ventures Sony Ventures Corporation British Business Bank +2 more

RQ Biorqbiotechnology.comJun 2026 · $115M

RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.

BiotechHealthtech

Co-investorsFrazier Life Sciences LifeArc Ventures Wellington Management EQT Life Sciences Forbion Monograph Capital Partners +1 more

Salience Labssaliencelabs.ai

Spin-out from the Universities of Oxford and Munster developing a novel semiconductor chip.

Vaysh Kewada(Founder)in

Co-investorsBorski Fund Cambridge Innovation Capital Perivoli Innovations Silicon Catalyst Applied Ventures Deeptech Labs

Scenic Biotechscenicbiotech.com in 𝕏

Scenic Biotech develops modifier therapy, a genetic medicine approach that targets secondary functions in the genome to neutralize the impact of disease-causing mutations.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtech

Co-investorsBioGeneration Ventures BioMedPartners EIR Ventures Inkef

Scripta Therapeuticsscriptatherapeutics.com inSeed · Nov 2025 · $12M

Scripta Therapeutics is a drug discovery company that maps and modulates transcription factors using AI/ML models and patient-derived disease models to identify novel therapeutics.

AI & Machine LearningBiotechDeep Tech

Co-investorsAlbionVC Apollo Health Ventures

SpyBiotechspybiotech.com in 𝕏

A biotech company dedicated to developing new vaccines, combining scientific expertise with commercial and operational capabilities.

BiotechDeep TechHealthtechMedical DevicesCambridge, GB

Mark Howarth(Co-founder)inSumi Biswas(President, Co-founder, Chief Scientific Officer)inSimon Draper(Co-founder)inJing Jin(Co-founder)in

Co-investorsGV (Google Ventures)Oxford

Stateful Roboticsstatefulrobotics.comMar 2026 · $4.8M

Stateful builds a decision intelligence engine that turns operational requirements into optimised, adaptive missions for mobile robots, coordinating single-robot, multi-robot, and human-robot operations across changing real-world environments.

AI & Machine LearningDeep TechRobotics

Kirsty Lloyd-Jukes(CEO & Co-Founder)inNick Hawes(Chief Scientist & Co-Founder)Bruno Lacerda(CTO & Co-Founder)inDavid Parker(Advisor & Co-Founder)

Co-investorsAmadeus Capital Partners Oxford University Innovation Amadeus Capital SA

T-Cypher Biotcypherbio.com in

T-Cypher Bio develops drugs with curative potential, focusing on antibody development, T cell biology, and TCR discovery.

AI & Machine LearningBiotechDeep Tech

Co-investorsFuture Planet Capital LifeArc Ventures Perivoli Innovations Medicxi

Tidaltidalcyber.com in 𝕏May 2026 · $5.6M

Tidal Cyber develops tools and services that help enterprises adopt MITRE ATT&CK framework for threat-informed defense.

CybersecurityEnterprise Software

Rick Gordon in

Co-investorsAccess Venture Partners Bright Pixel Capital Dreamit Ventures Glasswing Ventures StoneMill Ventures TFX Capital +10 more

Valink Therapeuticsvalinktx.com inSeries A · Oct 2025

Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.

AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US

Arne Scheu(Founder)in Irsyad Khairil(Founder)in

Co-investorsHoxton Ventures LongeVC Metaplanet Oxonian Ventures P53 Invest RV Invest GmbH +9 more

Vividvivid.money in 𝕏Jul 2026 · $15M

Vivid provides mobile business and personal banking for European small and medium-sized companies, offering online account opening, instant transfers, interest on cash balances, cashback cards, and investment options in stocks, ETFs, and cryptocurrencies.

FintechSaaS

Alex Emeshev(Founder)in

Co-investorsSoftBank Vision Fund Greenoaks Ribbit Capital

Wild Biosciencewildbioscience.com in

Ross Hendron(Founder)in

Yasayasa.com inacquired by Mercedes Benz

YASA develops axial flux electric motors ('eMotors') and control systems for electric vehicles and other electrification applications, using a proprietary Yokeless And Segmented Armature design that reduces motor size and weight while increasing power and torque density.

CleantechHardwareMobility & TransportationOxford, GB

Tim Woolmer(Founder & CTO)inJörg Miska(Chief Executive Officer)

Co-investors24 Haymarket Parkwalk Advisors Inovia Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Acionna TherapeuticsAlethio TherapeuticsAlethiotxAlloyedApplied AtomicsAscensionBase GenomicsBeacon TherapeuticsCaudal EnergyCircadian TherapeuticsCredo TherapiesDJS AntibodiesELIGENTISExposing cancer’s hidden vulnerabilitiesGround Truth LabsHEXRISOgenixKesmaleaKneu HealthLatent LogicMatchBioMirae HealthMiroBioMoa TechnologyNatcapOath SurgicalOdqa Renewable Energy TechnologiesORFonyxOsler DiagnosticsOxford EndovascularOxford NanoimagingRinri TherapeuticsSalienceScriptaStronger, lighter, fasterThelior BioVivid Dx

Exits · 3

2 IPOs · 1 acquisitions

BarinthusbioNASDAQ: BRNSPepGenNASDAQ: PEPGYasaacq. by Mercedes Benz

Portfolio news

latest coverage across their companies

Fractile in talks to raise at a $6.5bn valuation

Fractile · thenextweb.com · Aug 19, 2026

Refeyn continues participation in NIIMBL consortium tackling AAV purification - Refeyn

Refeyn · refeyn.com · Aug 11, 2026

RQ Bio Raises £85.5M in Series A Funding

RQ Bio · finsmes.com · Jun 24, 2026

BibliU Raises Over $55M in New Funding

Bibli U · finsmes.com · Jun 3, 2026

Every fusion startup that has raised over $100M

First Light Fusion · finance.yahoo.com · Apr 10, 2026

Amber Therapeutics strengthens its Board and Leadership team, opens UK headquarters and expands EU feasibility study for mixed urinary incontinence, increasing momentum towards a pivotal trial in the US

Amber Therapeutics · globenewswire.com · Feb 24, 2026

Dark Blue Therapeutics acquired by Amgen for up to $840 million

Dark Blue Therapeutics · prnewswire.com · Jan 6, 2026

Ultromics Secures Strategic Investment from the American Heart Association’s Go Red for Women Venture Fund - Ultromics

Ultromics · ultromics.com · Dec 17, 2025

Frequently asked questions

How many investments has Oxford Science Enterprises made?: Oxford Science Enterprises has 104 tracked investments, 3 of which have exited, including 9 dated in the last 24 months.
What stage does Oxford Science Enterprises invest at?: Oxford Science Enterprises invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth stages.
What is Oxford Science Enterprises's typical check size?: Oxford Science Enterprises typically writes checks of $63.5K – $31.8M.
What sectors does Oxford Science Enterprises focus on?: Oxford Science Enterprises focuses on AgTech, AI & Machine Learning, Biotech, Cleantech, Climate Tech, Deep Tech, Energy, Healthtech, Medical Devices, Quantum Computing, Robotics, Sector Agnostic.
Where is Oxford Science Enterprises located?: Oxford Science Enterprises is headquartered in Oxford, GB.
Does Oxford Science Enterprises lead rounds?: Yes, Oxford Science Enterprises leads investment rounds.
Who does Oxford Science Enterprises co-invest with?: Oxford Science Enterprises most often shares deals with Future Planet Capital, Perivoli Innovations, GV (Google Ventures), among 91 tracked co-investors.

Media · Podcasts & interviews

featuring the team

FII9: Ed Bussey – CEO, Oxford Science Enterprises

FII Institute · Ed Bussey

Ed Bussey, CEO of Oxford Science Enterprises, on the need for talent in the UK's spinout ecosystem.

Global Corporate Venturing · Ed Bussey

Ed Bussey, CEO, Oxford Science Enterprises

American European Business Association - AEBA · Ed Bussey

Bloomberg Talks: Oxford Science Enterprises CEO Ed Bussey | Bloomberg Talks

Bloomberg Podcasts · Ed Bussey

Images

Co-investors · 4

Parkwalk Advisors

Parkwalk Advisors is a UK-based investment manager focused on backing deeptech companies spun out of UK universities, bridging the gap between academic research and commercial success. It operates as part of IP Group plc and is a leading EIS fund manager.

Both backed · 8

Bibli U Mind Foundry Opsydia Proxisense Quantum Motion YasaMoa TechnologyOxford Endovascular

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 5

Barinthusbio Evox Therapeutics Omass SpyBiotech Ultromics

$250K – $50M

Apollo Health Ventures

Apollo Health Ventures is a biotech-focused investor that combines traditional funding with venture building to back transformative healthcare and longevity companies in Europe and the US.

Both backed · 1

Scripta Therapeutics

Borealis Ventures

Borealis Ventures is a venture capital firm focused on building and backing healthcare companies.

Both backed · 1

Orbit Discovery

$1M – $2.5M

Firms observed investing alongside Oxford Science Enterprises, from public investor directories. Shared companies are the overlap with Oxford Science Enterprises's recorded portfolio.

Similar investors

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Khosla Ventures

Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.

$100K – $20M

Artesian

Artesian is a deep tech and hardware venture capital investor that builds funds around specific institutional backers — governments, corporations, universities, industry bodies and super funds — to pursue both financial returns and strategic outcomes in critical industries.

$20M

BDC Fund Investments (Fund-of-Funds)

BDC (Business Development Bank of Canada) is a Canadian financial institution that has supported small and medium-sized businesses across all industries and stages of growth for over 80 years, providing financing and advisory services.

Innovation Industries

Innovation Industries is a Dutch deep-tech venture capital firm that builds and scales technology companies through hands-on, multidisciplinary support.

$2.2M – $54M